Published in Medical Letter on the CDC and FDA, July 21st, 2002
The test yielded a genetically based survival index for people with diffuse large-B-cell lymphomas. It is a better predictor than current methods, which consider a patient's age, the stage and spread of the disease, and similar factors, said Dr. Louis Staudt of the National Cancer Institute, who supervised the international study.
But he said both methods might eventually be used in tandem for the best possible prediction.
That could help doctors decide on the best course of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.